Amylyx Pharmaceuticals, Inc.
32.40USD
-1.4800 (-4.37%)
Fetching financial statements from SEC filings…
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 0 | 0 | 0 | -1 | 0 |
| Cost of Revenue | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | — | — | 0 | 0 | 0 | 0 | -1 | 0 |
| Operating Income | -46 | -44 | -37 | -36 | -43 | -38 | -41 | -76 |
| Net Income | -43 | -41 | -33 | -34 | -41 | -36 | -38 | -73 |
| EPS (Diluted) | $-0.39 | $-0.37 | $-0.28 | $-0.37 | $-0.46 | $-0.42 | $-0.54 | $-1.07 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)